Coeptis Therapeutics, Inc. (COEP)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Coeptis Therapeutics, Inc. (COEP) trades at $10.45 with AI Score 51/100 (Hold). Coeptis Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing pharmaceutical products and cell therapy platforms for cancer patients. Market cap: 66M, Sector: Healthcare.
Last analyzed: Feb 8, 2026Coeptis Therapeutics, Inc. (COEP) Healthcare & Pipeline Overview
Coeptis Therapeutics is pioneering cancer treatment with its CD38-GEAR-NK cell therapy platform and CD38-Diagnostic tool, offering a personalized approach to cancer therapy and positioning the company for growth in the targeted oncology market, despite its current financial challenges.
Investment Thesis
Coeptis Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on targeted cancer therapies, particularly CD38-GEAR-NK, addresses a significant unmet need in the treatment of CD38-related cancers. The CD38-Diagnostic tool further enhances the value proposition by enabling personalized treatment selection. Key value drivers include the successful clinical development and commercialization of CD38-GEAR-NK, expansion of the product pipeline through strategic collaborations, and potential acquisition by a larger pharmaceutical company. While the company's negative P/E ratio of -5.48 and a high negative profit margin of -1948.8% raise concerns about its current financial performance, successful execution of its development programs could lead to significant revenue generation and shareholder value creation. Upcoming clinical trial results for CD38-GEAR-NK will serve as a major catalyst. Investors should closely monitor the company's cash burn rate and ability to secure additional funding.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.04 billion reflects the company's early stage and speculative nature.
- Negative P/E ratio of -5.48 indicates the company is currently unprofitable.
- Gross margin of 21.1% suggests potential for profitability as product commercialization progresses.
- Beta of -0.50 indicates the stock is less volatile than the market, but this may be due to its small size and limited trading volume.
- No dividend is paid, consistent with growth-oriented biotechnology companies that reinvest earnings.
Competitors & Peers
Strengths
- Proprietary CD38-GEAR-NK cell therapy platform.
- CD38-Diagnostic tool enables personalized treatment selection.
- Strategic collaborations expand pipeline and expertise.
- Focus on targeted therapies addresses unmet needs in oncology.
Weaknesses
- Limited financial resources.
- Small number of employees.
- Early stage of development with no products currently on the market.
- High dependence on successful clinical trials and regulatory approvals.
Catalysts
- Upcoming: Clinical trial data readouts for CD38-GEAR-NK.
- Upcoming: Regulatory submissions for CD38-GEAR-NK and CD38-Diagnostic.
- Ongoing: Progress in collaborations with Statera BioPharma and Vici Health Sciences.
- Ongoing: Potential for new strategic partnerships and acquisitions.
Risks
- Potential: Clinical trial failures for CD38-GEAR-NK or other pipeline products.
- Potential: Regulatory delays or rejection of product applications.
- Ongoing: Competition from larger pharmaceutical companies with greater resources.
- Ongoing: Difficulty in securing funding to support ongoing operations and development programs.
- Potential: Intellectual property disputes.
Growth Opportunities
- CD38-GEAR-NK Clinical Development: The successful completion of clinical trials and regulatory approval of CD38-GEAR-NK represents a significant growth opportunity. The market for CD38-targeted therapies is estimated to reach billions of dollars, driven by the prevalence of multiple myeloma and other CD38-expressing cancers. Positive clinical data could lead to rapid adoption by oncologists and generate substantial revenue for Coeptis. Timeline: Ongoing clinical trials with potential for data readouts in the next 12-24 months.
- CD38-Diagnostic Commercialization: The commercialization of CD38-Diagnostic as a companion diagnostic tool for anti-CD38 monoclonal antibody therapies offers a recurring revenue stream. By identifying patients most likely to respond to these therapies, CD38-Diagnostic can improve treatment outcomes and reduce healthcare costs. Timeline: Commercial launch expected within the next year, pending regulatory approvals and partnerships with diagnostic laboratories.
- STAT-201 Development for Crohn's Disease: The collaboration with Statera BioPharma to develop STAT-201 for Crohn's disease expands Coeptis' therapeutic focus beyond oncology. Crohn's disease is a chronic inflammatory bowel disease with a significant unmet need for effective therapies. Successful development of STAT-201 could generate substantial revenue and diversify Coeptis' pipeline. Timeline: Preclinical and early clinical development ongoing, with potential for Phase 2 trials within the next 2-3 years.
- CPT60621 Development for Parkinson's Disease: The co-development of CPT60621 with Vici Health Sciences for Parkinson's Disease offers another avenue for growth. Parkinson's Disease is a neurodegenerative disorder affecting millions worldwide. Successful development of CPT60621 could address a significant unmet need and generate substantial revenue. Timeline: Preclinical development ongoing, with potential for clinical trials within the next 3-5 years.
- Strategic Partnerships and Acquisitions: Coeptis can pursue strategic partnerships and acquisitions to expand its pipeline, access new technologies, and accelerate commercialization. Collaborations with larger pharmaceutical companies could provide access to funding, expertise, and distribution networks. Timeline: Ongoing, with potential for new partnerships and acquisitions in the next 12-24 months.
Opportunities
- Growing market for cancer therapies.
- Increasing demand for personalized medicine.
- Potential for strategic partnerships and acquisitions.
- Expansion into new therapeutic areas through collaborations.
Threats
- Competition from larger pharmaceutical companies.
- Regulatory hurdles and lengthy approval processes.
- Clinical trial failures.
- Difficulty in securing funding.
Competitive Advantages
- Proprietary cell therapy platform (CD38-GEAR-NK).
- Diagnostic tool (CD38-Diagnostic) that enables personalized treatment.
- Strategic collaborations with Statera BioPharma and Vici Health Sciences.
- Focus on targeted therapies addressing unmet needs in oncology.
About COEP
Coeptis Therapeutics, Inc., founded in 2017 and headquartered in Wexford, Pennsylvania, is a biopharmaceutical company dedicated to developing and commercializing innovative pharmaceutical products and cell therapy platforms for cancer patients. The company's core focus revolves around addressing unmet needs in oncology through targeted therapies and diagnostic tools. Its lead product, CD38-GEAR-NK, is a Vy-Gen drug product designed for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia. This novel therapy leverages the power of natural killer (NK) cells to target and eliminate cancer cells expressing the CD38 protein. Complementing CD38-GEAR-NK is CD38-Diagnostic, an in vitro screening tool that enables clinicians to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibody therapies. This personalized approach aims to improve treatment outcomes and reduce unnecessary exposure to ineffective therapies. Coeptis Therapeutics also engages in strategic collaborations to expand its pipeline and address other disease areas. The company is collaborating with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease, and with Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. These partnerships demonstrate Coeptis' commitment to diversifying its therapeutic focus and leveraging external expertise to accelerate drug development.
What They Do
- Develop and commercialize cell therapy platforms for cancer treatment.
- Create pharmaceutical products for cancer patients.
- Focus on targeted therapies for specific cancer types.
- Develop CD38-GEAR-NK for CD38-related cancers.
- Offer CD38-Diagnostic as a tool to pre-determine treatment effectiveness.
- Collaborate with other companies to expand their product pipeline.
- Develop treatments for Crohn's disease and Parkinson's disease through partnerships.
Business Model
- Develop and license or commercialize proprietary pharmaceutical products and cell therapy platforms.
- Generate revenue through sales of diagnostic tools and therapies.
- Collaborate with other companies to share development costs and revenue.
- Seek funding through equity offerings, grants, and partnerships.
Industry Context
Coeptis Therapeutics operates in the competitive biotechnology industry, which is characterized by high R&D costs, lengthy development timelines, and regulatory hurdles. The market for cancer therapies is substantial and growing, driven by an aging population and increasing incidence of cancer. Coeptis' focus on targeted therapies aligns with the industry trend towards personalized medicine. Competitors include companies like CUE Biopharma (CUE), Equillium (EQ), and Kiadis Pharma (KPTI), which are also developing novel cancer immunotherapies. The success of Coeptis will depend on its ability to differentiate its products and secure regulatory approval in a timely manner.
Key Customers
- Cancer patients suffering from CD38-related cancers.
- Hospitals and oncology clinics.
- Diagnostic laboratories.
- Pharmaceutical companies seeking to license or acquire novel therapies.
Financials
Chart & Info
Coeptis Therapeutics, Inc. (COEP) stock price: $10.45 (-0.47, -4.30%)
Latest News
No recent news available for COEP.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for COEP.
Price Targets
Wall Street price target analysis for COEP.
MoonshotScore
What does this score mean?
The MoonshotScore rates COEP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
What Investors Ask About Coeptis Therapeutics, Inc. (COEP)
What does Coeptis Therapeutics, Inc. do?
Coeptis Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative pharmaceutical products and cell therapy platforms for cancer patients. Their primary focus is on targeted therapies, with their lead product being CD38-GEAR-NK, a cell therapy platform designed to treat CD38-related cancers like multiple myeloma. They also have CD38-Diagnostic, an in vitro screening tool that helps determine which patients are most likely to benefit from anti-CD38 monoclonal antibody therapies. Additionally, they engage in collaborations to develop treatments for other diseases like Crohn's and Parkinson's.
Is COEP stock worth researching?
COEP stock is a speculative investment with high potential upside and significant risks. The company's focus on targeted cancer therapies and personalized medicine aligns with industry trends, and successful development of CD38-GEAR-NK could generate substantial revenue. However, the company's negative P/E ratio and limited financial resources raise concerns about its ability to sustain operations and fund development programs. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in COEP. Monitor clinical trial results and funding announcements closely.
What are the main risks for COEP?
The main risks for COEP include clinical trial failures, regulatory delays or rejection of product applications, competition from larger pharmaceutical companies, and difficulty in securing funding. As a small biotechnology company with limited resources, COEP is highly dependent on the success of its clinical development programs and its ability to raise capital. Any setbacks in these areas could significantly impact the company's prospects and lead to a decline in its stock price. Additionally, intellectual property disputes could pose a threat to the company's proprietary technologies.
What are the key factors to evaluate for COEP?
Coeptis Therapeutics, Inc. (COEP) currently holds an AI score of 51/100, indicating moderate score. Key strength: Proprietary CD38-GEAR-NK cell therapy platform.. Primary risk to monitor: Potential: Clinical trial failures for CD38-GEAR-NK or other pipeline products.. This is not financial advice.
How frequently does COEP data refresh on this page?
COEP prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven COEP's recent stock price performance?
Recent price movement in Coeptis Therapeutics, Inc. (COEP) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary CD38-GEAR-NK cell therapy platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider COEP overvalued or undervalued right now?
Determining whether Coeptis Therapeutics, Inc. (COEP) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying COEP?
Before investing in Coeptis Therapeutics, Inc. (COEP), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may not be entirely accurate or complete.
- Investment in biotechnology companies is highly speculative and involves significant risks.